| Mcl-1 inhibition: managing malignancy in multiple myeloma OS Al-Odat, M von Suskil, RJ Chitren, WO Elbezanti, SK Srivastava, ... Frontiers in Pharmacology 12, 699629, 2021 | 32 | 2021 |
| Autophagy and apoptosis: current challenges of treatment and drug resistance in multiple myeloma OS Al-Odat, DA Guirguis, NK Schmalbach, G Yao, T Budak-Alpdogan, ... International Journal of Molecular Sciences 24 (1), 644, 2022 | 20 | 2022 |
| Bruton’s tyrosine kinase targeting in multiple myeloma M Von Suskil, KN Sultana, WO Elbezanti, OS Al-Odat, R Chitren, ... International journal of molecular sciences 22 (11), 5707, 2021 | 19 | 2021 |
| Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like … WO Elbezanti, OS Al-Odat, R Chitren, JK Singh, SK Srivastava, K Gowda, ... Frontiers in Pharmacology 13, 894535, 2022 | 11 | 2022 |
| Cancer on fire: role of inflammation in prevention and treatment MK Pandey, M Von Suskil, R Chitren, O Al-Odat, SC Jonnalagadda, ... Current advances for development of functional foods modulating inflammation …, 2022 | 6 | 2022 |
| Pathways to Therapy Resistance: The Sheltering Effect of the Bone Marrow Microenvironment to Multiple Myeloma Cells K Bhowmick, M von Suskil, OS Al-Odat, WO Elbezanti, SC Jonnalagadda, ... Heliyon, 2024 | 3 | 2024 |
| A novel Mcl-1 inhibitor induces cells death in a caspase-dependent manner and increases the efficacies of Venetoclax and ABT-737 in multiple myeloma cells OS Al-Odat, RS Tripathi, SK Srivastava, K Gowda, SG Amin, ... Cancer Research 82 (12_Supplement), 3952-3952, 2022 | 2 | 2022 |
| KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis OS Al-Odat, WO Elbezanti, K Gowda, SK Srivastava, SG Amin, ... Frontiers in pharmacology 15, 1436786, 2024 | 1 | 2024 |
| Discovering potential in non-cancer medications: A promising breakthrough for multiple myeloma patients OS Al-Odat, E Nelson, T Budak-Alpdogan, SC Jonnalagadda, D Desai, ... Cancers 16 (13), 2381, 2024 | 1 | 2024 |
| Drug Resistance Can be Overcome in Multiple Myeloma and Acute Myeloid Leukemia By Targeting Mcl-1 with the Small Chemical KS18 OS Al-Odat, R Chitren, M Von Suskil, O Aloudat, K Gowda, ... Blood 142, 5771, 2023 | 1 | 2023 |
| Mcl-1 inhibitor KS18 overcomes bortezomib, venetoclax, and ABT-737 resistance in multiple myeloma OSA Odat, K Gowda, SG Amin, TB Alpdogan, SC Jonnalagadda, ... Cancer Research 83 (7_Supplement), 1748-1748, 2023 | 1 | 2023 |
| Selective Small Molecule Targeting of MCL-1 in Multiple Myeloma OS Al-Odat Rowan University, 2021 | 1 | 2021 |
| Plant‐based Nutraceuticals with Anticarcinogenic Potential OS Al‐Odat, G Yao, NK Schmalbach, DA Guirguis, O Aloudat, ... Herbal Nutraceuticals: Products and Processes, 155-186, 2024 | | 2024 |
| Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway? M Motlak, M Mathews, OS Al-Odat, MK Pandey Cytokine 179, 156629, 2024 | | 2024 |
| A New Hope for Multiple Myeloma: Harnessing the Power of Non-Cancer Medications OSF Al-Odat, E Nelson, T Budak-Alpdogan, SC Jonnalagadda, D Desai, ... Preprints, 2024 | | 2024 |
| Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells O Aloudat, OS Al Odat, T Budak-Alpdogan, S Jonnalagadda, Y Chen, ... Cancer Research 84 (6_Supplement), 7218-7218, 2024 | | 2024 |
| The development of a small molecule dual inhibitor of CXCR4 and Mcl-1 to target bortezomib resistant and stem-like cells in multiple myeloma WO Elbezanti, OS Al-Odat, SC Jonnalagadda, T Budak-Alpdogan, ... Cancer Research 84 (6_Supplement), 4477-4477, 2024 | | 2024 |
| KS18, an Mcl-1 inhibitor, triggers cell death and enhances the therapeutic efficacy of venetoclax in bortezomib-resistant multiple myeloma cells OSA Odat, O Aloudat, E Nelson, T Budak-Alpogan, S Jonnalagadda, ... Cancer Research 84 (6_Supplement), 4670-4670, 2024 | | 2024 |
| Investigating the Therapeutic Potential of Soursop in Treating Hematologic Malignancies SM Paparo, R Mendoza, R Chitren, O Al-Odat, E Nelson, S Jonnalagadda, ... | | 2024 |
| Efficacy of Mcl-1 Inhibitors in Multiple Myeloma Cells Resistant to Bortezomib E Nelson, OS Al-Odat, SM Paparo, DA Guirguis, G Yao, M Pandey, ... | | 2024 |